Connection

Jinghua Yan to Double-Blind Method

Back to Details
This is a "connection" page, showing publications Jinghua Yan has written about Double-Blind Method.
Jinghua Yan
Connection Strength
0.069
Double-Blind Method
  1. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrob Agents Chemother. 2021 07 16; 65(8):e0035021.
    View in: PubMed
    Score: 0.025
  2. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021 08; 21(8):1107-1119.
    View in: PubMed
    Score: 0.024
  3. CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2017 12; 107:5-12.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.